After the COVID Boom: BioNTech Reinvents in the Face of Financial Tides
BioNTech navigates post-pandemic challenges as COVID-19 vaccine profits decline, prompting strategic realignment. Quarterly earnings fell from €1.90 to €1.08 per share, yet exceeded market expectations of €0.407 per share. Focus…